Pharmacy Perspectives in Multiple Myeloma: Relapsed and/or Refractory Disease

Program Goals

MM Epidemiology

MM Pathophysiology

MM Treatment Considerations and Approaches

MM Relapsed vs Refractory

RRMM When to Consider Treatment

RRMM Treatment Factors to Consider

RRMM Treatment Options

RRMM Case Study 1

Question

Bortezomib Management of Neuropathy

Case Study 1 Progressive Disease

Question

Carfilzomib Phase 2 Trial (PX-171-003-A1)

Phase 2 Trial (PX-171-003-A1) Efficacy

Carfilzomib Phase 2 Trials Grade 3/4 Toxicity (Noncardiac)

Carfilzomib Phase 2 Trials Cardiac Toxicity

Carfilzomib Management of Cardiac Events

RRMM Case Study 2

Question

MM-002 Phase 2 Trial Design

MM-002 Phase 2 Trial Outcomes

MM-002 Phase 2 Trial Grade 3/4 Adverse Events

MM-003 Phase 3 Trial Design

MM-003 Phase 3 Trial Outcomes

RRMM Case Study 3

Question

ASPIRE Phase 3 Trial Design

ASPIRE Phase 3 Trial Efficacy

ASPIRE Phase 3 Trial Grade ≥ 3 Toxicity

MM Selected Dose Modifications

MM Supportive Care

MM Selected Novel Agents

Pharmacy Perspectives in RRMM Summary

Abbreviations

Abbreviations (cont)

Abbreviations (cont)

Abbreviations (cont)

Abbreviations (cont)

References

References (cont)

References (cont)

References (cont)

References (cont)

References (cont)